Eyenovia Overview

  • Founded

  • 2014

Founded
  • Status

  • Public

  • Employees

  • 41

Employees
  • Stock Symbol

  • EYEN

Stock Symbol
  • Share Price

  • $2.98

  • (As of Friday Closing)

Eyenovia General Information

Description

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Contact Information

Website
www.eyenoviabio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 295 Madison Avenue
  • Suite 2400
  • New York, NY 10017
  • United States
+1 (917) 000-0000

Eyenovia Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eyenovia Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.98 $3.10 $1.50 - $5.85 $118M 38M 468K -$0.75

Eyenovia Financials Summary

In Thousands,
USD 		TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 121,371 48,708 107,410 128,504
Revenue 0 0 14,000 2,000
EBITDA (24,568) (26,407) (12,172) (19,684)
Net Income (26,411) (28,011) (12,778) (19,770)
Total Assets 29,309 31,036 31,659 33,907
Total Debt 10,996 10,123 7,150 463
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eyenovia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eyenovia‘s full profile, request access.

Request a free trial

Eyenovia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array p
Drug Delivery
New York, NY
41 As of 2022
000.00
000000 - 000 000.00

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000 00000000
Bedford, MA
000 As of 0000
00000
000000 - 000 00000

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 00000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eyenovia Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ocular Therapeutix Formerly VC-backed Bedford, MA 000 00000 000000 - 000 00000
000000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000 Corporation Durham, NC 00 000.00 000000000 000.00
000000 00000000000 Formerly VC-backed Mountain View, CA 000 00000 000000&0 00000
000000 Venture Capital-Backed Salt Lake City, UT 0 00.000 0000000000 00.000
You’re viewing 5 of 12 competitors. Get the full list »

Eyenovia Patents

  • 110

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 11

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Eyenovia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020399803-A1 Systems and devices for delivering fluids to the eye and methods of use Pending 11-Dec-2019 0000000000
CA-3164288-A1 Systems and devices for delivering fluids to the eye and methods of use Pending 11-Dec-2019 0000000000
EP-4072483-A1 Systems and devices for delivering fluids to the eye and methods of use Pending 11-Dec-2019 0000000000
JP-2023506781-A Systems and devices for delivering fluids to the eye and methods of use Pending 11-Dec-2019 0000000000
US-20210177650-A1 Systems and devices for delivering fluids to the eye and methods of use Pending 11-Dec-2019 A61F9/0008
To view Eyenovia’s complete patent history, request access »

Eyenovia Executive Team (5)

Name Title Board Seat Contact Info
Michael Rowe Chief Executive Officer & Board Member
John Gandolfo Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Earnest Mario Ph.D Director
Fredric Eshelman Chairman
You’re viewing 4 of 5 executive team members. Get the full list »

Eyenovia Board Members (13)

Name Representing Role Since
Charles Mather Eyenovia Board Member 000 0000
Ellen Strahlman Self Board Member 000 0000
Ernest Mario Ph.D Self Board Member 000 0000
Fredric Eshelman Self Chairman 000 0000
Kenneth Lee Jr. Self Lead Director 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Eyenovia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial